Ibodutant

From Self-sufficiency
Revision as of 09:15, 8 February 2010 by El3ctr0nika (Talk) (Stub to bottom.)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Ibodutant
150px
Systematic (IUPAC) name
Nα-[(1-{[(6-methyl-1-benzothien-2-yl)carbonyl]amino}cyclopentyl)carbonyl]-N-{[1-(tetrahydro-2H-pyran-4-ylmethyl)piperidin-4-yl]methyl}-D-phenylalaninamide
Clinical data
Routes of
administration		 Oral
Identifiers
ATC code none
PubChem CID 11527495
Synonyms 6-methyl-N-[1-[[(2R)-1-[[1-(oxan-4-ylmethyl)piperidin-4- yl]methylamino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]cyclopentyl]-1-benzothiophene-2-carboxamide
Chemical data
Formula C37H48N4O4S
Molar mass 644.866 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Ibodutant is a candidate drug against irritable bowel syndrome, developed by The Menarini Group. As of May 2008, it is undergoing a multicentre double blind dose finding study.

Method of action

Ibodutant selectively blocks the tachykinin receptor NK2. Blockage is practically complete in nanomolar concentrations.

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
  • H. Spreitzer (May 26, 2008). "Neue Wirkstoffe - Ibodutant". Österreichische Apothekerzeitung (in German) (11/2008): 541. 
  • S. Giuliani, M. Altamura, C. A. Maggi. "Ibodutant. Tachykinin NK2 receptor antagonist, Treatment of irritable bowel syndrome". Drugs of the Future. 33 (2): 111–115. 



Stub icon This pharmacology-related article is a stub. You can help ssf by expanding it.
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Ibodutant&oldid=23595"